Washington University

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. AbbVie, Caraway Research Targets TMEM17

Who: Eli Lilly/Disarm Therapeutics What: Lilly is making its second acquisition of the year, buying privately held Disarm and its preclinical SARM1 inhibitor program for axonal degeneration indicat

Who: Roche/Genentech and UCB What: Roche obtains worldwide licensing rights to anti-tau UCB0107, with UCB slated to conduct a proof-of-concept study with the antibody in Alzheimer’s, after which Ro

Below is Scrip’s regular roundup, including information from Strategic Transactions , of recent technology transfer agreements between companies and academic or other research institutions. Cincinna